TIGIT (T cell Ig and ITIM domain) is a member of the Poliovirus Receptor (PVR) / Nectin family. It consists of an extracellular immunoglobulin variable domain (IgV), a type I transmembrane domain, and intracellular domains with a classical immunoreceptor tyrosine-based inhibitory motif (ITIM) and an immunoglobulin tyrosine tail (ITT) motif. CD155 (PVR) is a high-affinity ligand for TIGIT. Once the highly expressed CD155 on tumor surfaces binds to TIGIT on the surface of NK and T cells, their cytotoxic effects on tumor cells are inhibited. Blocking TIGIT safely and effectively in the clinical setting has become a technical challenge for many medical researchers based on the TIGIT axis principle and the complex immune inhibitory patterns in the tumor microenvironment. The in vitro activity testing of Anti-TIGIT antibody drugs is the first step towards clinical application.The TIGIT CD226 Reporter Jurkat Cell Line uses engineered Jurkat cells as effector cells, stably expressing TIGIT/CD226 receptors and firefly luciferase driven by responsive elements. The biological activity of Anti-TIGIT in the TIGIT mechanism is quantified through luciferase, and the luciferase activity in effector cells is quantified through bioluminescence readings. Therefore, it can be used for the activity testing of functional antibodies targeting TIGIT.
